The Citalopram CIT-MD-18 Pediatric Depression Trial: A Deconstruction of Medical Ghostwriting, Data Manipulation and Academic Malfeasance
Abstract
This paper is a deconstruction of a ghostwritten report of a randomized, double-blind, placebo-controlled efficacy and safety trial of citalopram in depressed children and adolescents conducted in the United States. Court documents revealed that protocol-specified outcome measures showed no statistically significant difference between citalopram and placebo. However, the published article concluded that citalopram was safe and significantly more efficacious than placebo for children and adolescents, with possible adverse effects on patient safety.